Genetic Marker for FQAD, Drug Toxicity, and Vaccine Toxicity

Description:

Reference #1296: Genetic Marker for FQAD

 

The University of South Carolina is offering licensing opportunities for a genetic marker for Fluoroquinolone-Associated Disability (FQAD), drug toxicity, and vaccine toxicity.

 

Background:

Medication and vaccine adverse events can result in patient injuries, sometimes lethal or permanent. Fluoroquinolone-Associated Disability is a cluster of symptoms related to adverse reactions that lead to disability in patients who were reported to be previously healthy and prescribed an oral fluoroquinolone antibacterial drug for the treatment of simple infections and inflammations. There is a significant healthcare need for testing that can help providers make informed decisions regarding medication and vaccine selection and dosing in the context of a personalized medicine approach. Additionally, medication and vaccine adverse events result in significant additional cost to the healthcare system.

 

Invention Description:

Certain genes are considered to be a factor in medication and vaccine metabolism and toxicity. A bundle of CYP, ABC, SLCO, and SLC genes has been selected to be analyzed prior to medication consumption and vaccine administration in order to help medical providers determine the optimal type and dose of medication and vaccines (using a blood sample for this genetic testing).

 

Potential Applications:

This genetic testing bundle will help medical providers and patients make more informed decisions regarding medication and vaccine selection and medication and vaccine dosing in the context of personalized medicine approach.

 

Advantages and Benefits:

For medical providers, the bundled genetic testing package enables a focused ability to provide additional information to physicians in order to help determine the optimal type and dose of medication and vaccines for the patient.

 

For patients, the genetic testing package will assist patients in making more informed decisions (in conjunction with their medical providers) regarding medication and vaccine selection and dosing in the context of a personalized medicine approach.

 

For insurance providers, the testing package will save overall healthcare costs by helping to prevent medication and vaccine toxicity and adverse events in the context of a personalized medicine approach.

 

For the public health system, patients are more likely to comply with recommended medication and vaccine protocols if they are making more informed decisions (in conjunction with their medical providers) regarding medication and vaccine selection and medication and vaccine dosing in the context of a personalized medicine approach.

 

Patent Information:
Category(s):
Health Sciences
For Information, Contact:
Technology Commercialization
University of South Carolina
technology@sc.edu
Inventors:
Zaina Qureshi
Phillip Buckhaults
Carolyn Banister
Charles Bennett
Linda Martin
Keywords:
© 2018. All Rights Reserved. Powered by Inteum